Avalo Therapeutics Inc (AVTX) support and resistance · P/E 0.0, rev $441.0K
Avalo Therapeutics Inc (AVTX) is a biotechnology company listed on US.
This page maps Avalo Therapeutics Inc (AVTX) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported AVTX revenue for 2024-12-31 was $441.0K. Net income was -$35.1M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AVTX currently screens at market cap $51.5M and trailing P/E 0.0.
AVTX currently screens at market cap $51.5M and trailing P/E 0.0. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new AVTX 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the AVTX quote page for the session range and the stock page for the full model.
Not investment advice.